Brodalumab, an interleukin (IL) 17 inhibitor, is currently in early clinical trials (Phase 1b and Phase 2) for a number of different autoimmune diseases.1 Amgen recently terminated its co-development and commercialization agreement with AstraZeneca for the brodalumab investigational program in trials for moderate to severe plaque psoriasis, psoriatic arthritis and axial spondyloarthritis. Amgen’s decision to…
As the literature on comorbidities linked to psoriatic arthritis (PsA) expands, it’s becoming more difficult for clinicians to keep up with what comorbidities should be assessed and how these comorbidities affect treatment selection. Given this, rheumatologists at the Perelman School of Medicine at University of Pennsylvania, Cleveland Clinic and Hospital for Special Surgery in New…
The first biosmilar products have been approved in the U.S. and Canada, following Europe’s early lead. Canada approved its first biosimilar monoclonal antibody (mAb) therapy, known as Inflectra (infliximab), on March 30, 2015.1 In Canada, biosimilars are being called subsequent entry biologic (SEB) agents. Inflectra is approved for treating patients with rheumatoid arthritis (RA), ankylosing…
Plus, updates on arhalofenate, ALO-02, and other rheumatology drug news, safety information
Recognizing psychological effects of chronic conditions can help rheumatologists implement multidisciplinary approach to patient care
Experts highlight research on the overlap in innate and acquired immune responses underlying rheumatic diseases
Patients with conditions that don’t resolve with topical steroids are signal for referral
Consider a diagnosis of crusted scabies in immunosuppressed patients who develop a persistent, pruritic rash
Plus, updates on buprenorphine, diclofenac sodium, secukinumab and other rheumatology drug news, safety information
Clinical manifestations, approaches to diagnosis, treatment